

Daniel Douek

Discloser Identifier: 375483

Disclosure Purpose: 22-14293

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Meredith Gardner

Discloser Identifier: 1022141

Disclosure Purpose: 22-14293

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1101774

Disclosure Purpose: 22-14293

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1051417

Disclosure Purpose: 22-14293

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 996746

Disclosure Purpose: 22-14293

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

FRANCES Lee

Discloser Identifier: 984470

Disclosure Purpose: 22-14293

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Matthew Lee

Discloser Identifier: 1101773

Disclosure Purpose: 22-14293

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1103908

Disclosure Purpose: 22-14293

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1101776

Disclosure Purpose: 22-14293

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 984432

Disclosure Purpose: 22-14293

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 382909

Disclosure Purpose: 22-14293

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 325572

Disclosure Purpose: 22-14293

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Foundation for the National Institutes of Health	Grant / Contract	Self
<i>Recipient Name:</i> Nadine Rouphael <i>Grant / Contract Description:</i> VTEU- HIPC- T32 and R38 <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Laboratorios Pfizer Ltda.	Grant / Contract	Self
<i>Recipient Name:</i> Nadine Rouphael <i>Grant / Contract Description:</i> Clinical Study <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Merck	Grant / Contract	Self
<i>Recipient Name:</i> Emory <i>Grant / Contract Description:</i> Clinical Study <i>Additional Information:</i> Research on pneumococcal epidemiology		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
National Institutes of Health	Grant / Contract	Self
<i>Recipient Name:</i> Emory <i>Grant / Contract Description:</i> 5UM1AI148576-02 <i>Additional Information:</i> COVID-19 vaccines and therapeutics studies		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
SANOPI PASTEUR INC.	Grant / Contract	Self
<i>Recipient Name:</i> Emory <i>Grant / Contract Description:</i> Clinical studies <i>Additional Information:</i> On COVID-19 and C diff vaccines		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Hady Samaha

Discloser Identifier: 1087238

Disclosure Purpose: 22-14293

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Daniel Solis

Discloser Identifier: 1019433

Disclosure Purpose: 22-14293

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 942851

Disclosure Purpose: 22-14293

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
ModernaTX	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Consultation service to ModernaTX on the Epidemiology COVID-19 Variant Advisory Board <i>Additional Information:</i>		
Ocugen	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> I serve in an advisory role for Ocugen <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

Yes.

a. **Please list the other authors' names here.**

Meredith E. Davis-Gardner, Ph.D.1, Lilin Lai, M.D.1, Bushra Wali, Ph.D.1, Hady Samaha, M.D.1, Daniel Solis, B.S.2, Matthew Lee, M.S.1, Andrea Porter-Morrison, B.S.1, Ian Thomas Hentenaar, M.S.1, Fumiko Yamamoto, Ph.D.2, Sucheta Godbole, M.S.3, Yuan Li, Ph.D., M.S.,1 Daniel C. Douek, M.D., Ph.D.3, Frances Eun-Hyung Lee, M.D.,1, Nadine Roupheal, M.D.1, Alberto Moreno, M.D.1, Benjamin A. Pinsky, M.D., Ph.D.2, Mehul S. Suthar, Ph.D.1*

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1101777

Disclosure Purpose: 22-14293

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 923793

Disclosure Purpose: 22-14293

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Enhanced Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.